Healthcare Professional Survey to Assess the Effectiveness of Risk Evaluation and Mitigation Strategy for Dulaglutide (36 Month) (H9X-MC-B003)

Study identification

• EU PAS number:
  EUPAS20159
• Study ID:
  20646
• Official title and acronym:
  Healthcare Professional Survey to Assess the Effectiveness of Risk Evaluation and Mitigation Strategy for Dulaglutide (36 Month) (H9X-MC-B003)
• DARWIN EU® study:
  No
• Study countries:
  United States
• Study description:
  This study aims to assess the impact of Risk Evaluation and Mitigation Strategy (REMS) for dulaglutide on healthcare professional knowledge regarding the risk of pancreatitis and the potential risk of medullary thyroid carcinoma associated with dulaglutide therapy. The study will be conducted in the United States at 36 months after initial approval of the REMS.
• Study status:
  Ongoing

Research institutions and networks

Institutions

Nielsen

Study timelines

Date when funding contract was signed

Planned:30/04/2017

Study start date

Planned:15/05/2017

Actual:15/05/2017

Date of final study report

Planned:15/08/2017

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Eli Lilly and Company

Regulatory

• Was the study required by a regulatory body?:
  Yes
• Is the study required by a Risk Management Plan (RMP)?:
  Non-EU RMP only